WO2023233290 - RNAI AGENTS TARGETING PD-L1
National phase entry is expected:
Publication Number
WO/2023/233290
Publication Date
07.12.2023
International Application No.
PCT/IB2023/055528
International Filing Date
30.05.2023
Title **
[English]
RNAI AGENTS TARGETING PD-L1
[French]
AGENTS D'ARNI CIBLANT PD-L1
Applicants **
JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Barnahely Ringaskiddy
Co Cork, IE
Inventors
JIN, Yi
c/o Janssen Research & Development, LLC
920 US Route 202
PO Box 300
Raritan, New Jersey 08869, US
VAN GULCK, Ellen Rosalie A
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse, BE
OLLMANN, Michael Martin
c/o Janssen Research & Development, LLC
920 US Route 202
PO Box 300
Raritan, New Jersey 08869, US
RAMASESHAN, Mahesh
c/o Janssen Research & Development, LLC
920 US Route 202
PO Box 300
Raritan, New Jersey 08869, US
Priority Data
63/365,533
31.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2975 | |
| EPO | Filing, Examination | 17188 | |
| Japan | Filing | 529 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 10535 |
Total: 31802 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described are RNA interference (RNAi) agents for inhibiting the expression of PD-L1, and compositions comprising the RNAi agents and methods of administering same. The RNAi agents are useful in the treatment of diseases, such as, for example, HBV infection, HDV infection, and/or cancer, more particularly chronic HBV infection.[French]
L'invention concerne des agents d'interférence ARN (ARNi) pour inhiber l'expression de PD-L1, et des compositions comprenant les agents d'ARNi et des procédés d'administration de ceux-ci. Les agents d'ARNi sont utiles dans le traitement de maladies, telles que, par exemple, une infection par le VHB, une infection par le VHD et/ou un cancer, plus particulièrement une infection chronique par le VHB.